Literature DB >> 19995538

Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity.

Jennifer A McWilliams1, Phillip J Sanchez, Catherine Haluszczak, Laurent Gapin, Ross M Kedl.   

Abstract

We have previously shown that Toll-like receptor (TLR) agonists cooperate with CD40 to generate CD8 T cell responses exponentially larger than the responses generated with traditional vaccine formulations. We have also shown that combined TLR agonist/anti-CD40 immunization uniquely induces the upregulation of CD70 on antigen bearing dendritic cells (DCs). In contrast, immunization with either a TLR agonist or a CD40 stimulus alone does not significantly increase CD70 expression on DCs. Furthermore, the CD8(+) T cell response generated by combined TLR agonist/anti-CD40 immunization is dependent on the expression of CD70 by DCs, as CD70 blockade following immunization dramatically decreases the CD8 T cell response. Here we show that other innate pathways, independent of the TLRs, can also cooperate with CD40 to induce potent, CD70 dependent, CD8 T cell responses. These innate stimuli include Type I IFN (IFN) and alpha-galactosylceramide (alphaGalCer) or aC-GalCer, glycolipids that are presented by a nonclassical class I MHC molecule, CD1d, and are able to activate NKT cells. Furthermore, this combined IFN/anti-CD40 immunization generates protective memory against bacterial challenge with Listeria monocytogenes. Together these data indicate the importance of assessing CD70 expression on DCs as a marker for the capacity of a given vaccine formulation to potently activate cellular immunity. Our data indicate that optimal induction of CD70 expression requires a coordinated stimulation of both innate (TLR, IFN, alphaGalCer) and adaptive (CD40) signaling pathways. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995538      PMCID: PMC2822033          DOI: 10.1016/j.vaccine.2009.11.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  60 in total

1.  Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta.

Authors:  Vanessa Durand; Simon Yc Wong; David F Tough; Agnes Le Bon
Journal:  Immunol Cell Biol       Date:  2004-12       Impact factor: 5.126

2.  Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs.

Authors:  Vadim Y Taraban; Tania F Rowley; Aymen Al-Shamkhani
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

3.  Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.

Authors:  Julie M Curtsinger; Javier O Valenzuela; Pujya Agarwal; Debra Lins; Matthew F Mescher
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

4.  Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

Authors:  Ulrike Wille-Reece; Chang-You Wu; Barbara J Flynn; Ross M Kedl; Robert A Seder
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

5.  Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection.

Authors:  Colin Havenar-Daughton; Ganesh A Kolumam; Kaja Murali-Krishna
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

6.  CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.

Authors:  H Akiba; H Oshima; K Takeda; M Atsuta; H Nakano; A Nakajima; C Nohara; H Yagita; K Okumura
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

7.  Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells.

Authors:  Timothy N J Bullock; Hideo Yagita
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

8.  Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.

Authors:  Manuela Flórido; Margarida Borges; Hideo Yagita; Rui Appelberg
Journal:  J Leukoc Biol       Date:  2004-08-17       Impact factor: 4.962

9.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

10.  Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines.

Authors:  David C Tscharke; Gunasegaran Karupiah; Jie Zhou; Tara Palmore; Kari R Irvine; S M Mansour Haeryfar; Shanicka Williams; John Sidney; Alessandro Sette; Jack R Bennink; Jonathan W Yewdell
Journal:  J Exp Med       Date:  2004-12-28       Impact factor: 14.307

View more
  24 in total

1.  TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Authors:  Jason Z Oh; Jonathan S Kurche; Matthew A Burchill; Ross M Kedl
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

Review 2.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

3.  IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization.

Authors:  Nathan D Pennock; Laurent Gapin; Ross M Kedl
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

Review 4.  TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-07-24       Impact factor: 7.486

5.  CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Authors:  Han Dong; Nathan A Franklin; Shane B Ritchea; Hideo Yagita; Martin J Glennie; Timothy N J Bullock
Journal:  Eur J Immunol       Date:  2015-11-06       Impact factor: 5.532

Review 6.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

7.  Acute Virus Control Mediated by Licensed NK Cells Sets Primary CD8+ T Cell Dependence on CD27 Costimulation.

Authors:  Jeffrey J Teoh; Awndre E Gamache; Alyssa L Gillespie; Michael D Stadnisky; Hideo Yagita; Timothy N J Bullock; Michael G Brown
Journal:  J Immunol       Date:  2016-10-24       Impact factor: 5.422

8.  IL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses.

Authors:  Beth A Tamburini; Ross M Kedl; Donald Bellgrau
Journal:  J Immunother       Date:  2012-01       Impact factor: 4.456

9.  Lung dendritic cells at the innate-adaptive immune interface.

Authors:  Tracy Voss Condon; Richard T Sawyer; Matthew J Fenton; David W H Riches
Journal:  J Leukoc Biol       Date:  2011-08-01       Impact factor: 4.962

10.  Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.

Authors:  Jordana G Coelho-Dos-Reis; Jing Huang; Tiffany Tsao; Felipe V Pereira; Ryota Funakoshi; Hiroko Nakajima; Haruo Sugiyama; Moriya Tsuji
Journal:  Clin Immunol       Date:  2016-04-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.